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Abstract
Background: Human mesenchymal stromal cells (hMSC) are multipotent cells with both regenerative and
immunomodulatory activities making them an attractive tool for cellular therapy. In the last few years it has been
shown that the beneficial effects of hMSC may be due to paracrine effects and, at least in part, mediated by
extracellular vesicles (EV). EV have emerged as important mediators of cell-to-cell communication. Flow cytometry (FCM)
is a routine technology used in most clinical laboratories and could be used as a methodology for hMSC-EV
characterization. Although several reports have characterized EV by FCM, a specific panel and protocol for hMSC-derived
EV is lacking. The main objective of our study was the characterization of hMSC-EV using a standard flow cytometer.
Methods: Human MSC from bone marrow of healthy donors, mesenchymal cell lines (HS-5 and hTERT) and a leukemic
cell line (K562 cells) were used to obtain EV for FCM characterization. EV released from the different cell lines were
isolated by ultracentrifugation and were characterized, using a multi-parametric analysis, in a conventional flow
cytometer. EV characterization by transmission electron microscopy (TEM), western blot (WB) and Nano-particle tracking
analysis (NTA) was also performed.
Results: EV membranes are constituted by the combination of specific cell surface molecules depending on their cell of
origin, together with specific proteins like tetraspanins (e.g. CD63). We have characterized by FCM the EV released from
BM-hMSC, that were defined as particles less than 0.9 μm, positive for the hMSC markers (CD90, CD44 and CD73) and
negative for CD34 and CD45 (hematopoietic markers). In addition, hMSC-derived EV were also positive for CD63 and
CD81, the two characteristic markers of EV. To validate our characterization strategy, EV from mesenchymal cell lines
(hTERT/HS-5) were also studied, using the leukemia cell line (K562) as a negative control. EV released from mesenchymal
cell lines displayed the same immunophenotypic profile as the EV from primary BM-hMSC, while the EV derived from
K562 cells did not show hMSC markers. We further validated the panel using EV from hMSC transduced with GFP.
Finally, EV derived from the different sources (hMSC, hTERT/HS-5 and K562) were also characterized by WB, TEM and
NTA, demonstrating the expression by WB of the exosomal markers CD63 and CD81, as well as CD73 in those from
MSC origin. EV morphology and size/concentration was confirmed by TEM and NTA, respectively.
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Conclusion: We described a strategy that allows the identification and characterization by flow cytometry of hMSC-
derived EV that can be routinely used in most laboratories with a standard flow cytometry facility.
Keywords: Mesenchymal stromal cells, Flow cytometry, Extracellular vesicles characterization
Background
Human mesenchymal stromal cells (hMSC) are multipo-
tent adult stem cells that are not only able of differentiate
into most mesodermic cells [1] but also display a potent
immunomodulatory activity [2, 3]. These two properties
make them an attractive potential therapeutic tool for cell
therapy programs. hMSC can be isolated from most tis-
sues, although bone marrow (BM) and adipose tissue are
the cell sources most extensively used [4]. Although
hMSC have been successfully employed in many clinical
trials to date, the ultimate underlying therapeutic mecha-
nisms are still a matter of debate [5]. Pre-clinical studies
demonstrated a minimal contribution in direct tissue re-
pair (with the exception of bone regeneration) [6, 7].
Therefore, the beneficial effects of hMSC have been
mostly attributed to the paracrine secretion of soluble fac-
tors [8]. In addition, it has been recently described that
some of the effects of hMSC can be mediated through the
release of extracellular vesicles [9, 10]. The exchange of
EV is a complex and conserved mechanism of cell-to-cell
communication. EV are a heterogeneous population that
can be classified as exosomes or as shedding vesicles de-
pending on their origin [8, 11, 12]. When the vesicle is
formed from the inward of the endosomal membrane, it is
designated as an exosome which has a small size (30–
120 nm) and is secreted through exocytosis. Shedding vesi-
cles are generated by budding from the plasma membrane.
They are heterogeneous since their size (80–1000 nm) de-
pends on their cell of origin as well as the releasing stimuli
[13]. When released, EV can be incorporated into the re-
cipient cell by direct contact with the cell membrane by
their surface receptors or can be incorporated by mem-
brane fusion [14]. EV can transfer important biological in-
formation to the recipient cells, such as surface receptors,
proteins, mRNA, microRNA and bioactive lipids [15].
Structurally, EV membranes are enriched in cholesterol,
sphingomyelin, and ceramide (lipid rafts) [16–19].
EV sub-populations express specific proteins like tetra-
spanins (CD81, CD63, and CD9) and others depending on
their cell of origin [13, 20–22]. However it is difficult to
distinguish different sub-types of EV due to their overlap-
ping composition, density and size [10, 21], because of
that we adopted the term EV suggested by the Inter-
national Society for Extracellular Vesicles (ISEV) [23].
Bone marrow MSC-derived EV should express specific
markers of mesenchymal lineage (e.g. CD44) and also of
EV (e.g. CD63). Some of these molecules are critical for
EV biological action (e.g. CD44) and should be present in
these EV. The blockade of this latter cell surface glycopro-
tein deregulates vesicle uptake by tubular cells [24].
Flow cytometry (FCM) is a powerful methodology for
EV detection and characterization [25] in most clinical
laboratories. FCM is a technology that guides single par-
ticles through a laser beam in a hydro-dynamically fo-
cused fluid stream. The properties measured include
particle’s relative size, granularity or internal complexity,
and relative fluorescence intensity. These characteristics
are determined using an optical-to-electronic coupling
system that records how the cell or particle scatters inci-
dent laser light and emits fluorescence.
In general, the methodology is divided into two steps.
The first one is based on their side and forward scatter-
ing intensity, where the selection of the threshold value
is of extraordinary relevance. The detection of EV by
FCM used in most laboratories is a challenge since con-
ventional flow cytometers are not prepared to detect
events below 500 nm [26]. The second step for EV de-
tection is based on their specific labeling with fluores-
cent ligands.
The emergence of hMSC-derived EV (hMSC-EV) as a
new and potentially effective strategy in regenerative
medicine [27] has raised the need of more specific detec-
tion and characterization protocols. Although several re-
ports have characterized EV by FCM, a specific panel
and protocol for hMSC-EV FCM analysis is lacking. The
main objective of our study was to optimize hMSC-EV-
characterization methodology by FCM.
Methods
hMSC isolation, expansion and characterization
Bone marrow (BM) human mesenchymal stromal cells
(hMSC) were isolated from 5 healthy donors (three
males/two females) with a median age of 48 years (range
21–49 years). In all cases, written informed consent was
previously obtained according to institutional guidelines
and approved by the Comite Etico de Investigacion Clinica
del Area de Salud de Salamanca (located in Salamanca,
Spain) with reference number 70/07/2015. Mononuclear
cells (MNC) were isolated from fresh BM aspirates and
separated by density gradient centrifugation (Ficoll-Paque,
GE Healthcare Bio-Sciences, AB, Uppsala, Sweden) and
cultured in standard culture medium, as previously de-
scribed [7]. Cells were cultured at 37 °C in a humidified at-
mosphere with 5 % of carbon dioxide. At passage 3,
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hMSC characterization was performed according to the
recommendations of the International Society for Cellular
Therapy (ISCT) [28]. Isolation of hMSC-EV were per-
formed until passage number 6.
hMSC transduction
For transduction of hMSC we used a third generation of
replication-defective self-inactivating lentiviral vector. A
1.7 kb luciferase (Luc2) fragment was isolated from
pGL4.10 (Luc2) vector (Promega, Madison, WI) using
XhoI and NheI restriction sites. Subsequently, the Luc2
fragment was cloned in the LV pRRL-cPPT-CMV-IRES-
GFP-PRE-SIN (kindly provided by Prof. Hoeben, Leiden
University Medical Center, Leiden, Netherlands [46])
using the same restriction sites, downstream of the CMV
promoter, to generate pRRL-cPPT-CMV-Luc2-IRES-GFP-
PRE-SIN. The protocol of hMSC transduction performed
following procedures as previously reported [47] [48]. In
this study we used hMSC-GFP+ transduced with efficiency
over 60 %.
Cell lines
We isolated EV from human stromal cell lines to com-
pare them to EV derived from primary hMSC. The stro-
mal cell lines used were: hMSC-TERT, a hMSC cell line,
immortalized by expression of the telomerase reverse
transcriptase gene described by Mihara K et al. in 2003
[49], that was a generous gift from Dr. Dario Campana
(Department of Oncology and Pathology, St Jude Chil-
dren’s Research Hospital, Memphis, TN, USA) and the
fibroblastoid cell line HS-5, immortalized from human
bone marrow using the E6 and E7 human papillomavirus
genes, purchased from ATCC (ATCC® CRL11882™).
We also used K562 cells (a human cell line derived
from a patient with Philadelphia translocation-Ph+- blast
crisis) purchased from ATCC (ATCC® CCL243™), as a
negative control for immunophenotypic assays.
These cell lines were grown in Dulbecco’s modified
Eagle’s medium (DMEM; Gibco, Paisley, UK) (hMSC-
TERT and HS-5) or RPMI 1640 medium (DMEM;
Gibco, Paisley, UK) (K562) supplemented with 10 % fetal
bovine serum (FBS, Gibco, Paisley, UK), 100 U/mL peni-
cillin and 100 mg/mL streptomycin (Gibco, Paisley, UK).
All cell types were cultured at 37 °C in a humidified at-
mosphere in the presence of 5 % CO2–95 % air.
Preparation of conditioned medium and isolation of EV
EV were purified from the supernatants of hMSC (from
healthy donors), hMSC–GFP+, hMSC-TERT, HS-5 and
K562 cell lines. Briefly, cells were washed with phos-
phate–buffered saline (PBS) and then were cultured in
RPMI with antibiotic and deprived of FBS. After incuba-
tion for 24 h, the conditioned medium was collected and
centrifuged at 2000 g for 20 min at 4 °C to remove the
cell debris. In some cases, mainly when the supernatant
was obtained from many culture flasks, this supernatant
was filtered through a 0.22 μm filter (Millipore, Billerica,
MA) to remove debris. Then, the conditioned medium
(CM) was ultracentrifuged at 100,000 g for 70 min at 4 °C.
The pellets were then washed with doubled filtered PBS
and ultracentrifuged at 100,000 g for 70 min at 4 °C and
suspended in PBS (doubled filtered). All the samples were
ultracentrifuged in polycarbonate tubes (25 mm× 89 mm,
Beckman Coulter) that have a volume of 22 ml. A Beckman
Coulter ultracentrifuge (Beckman Coulter OptimaL-90K
ultracentrifuge; Beckman Coulter, Fullerton, CA, USA)
was used with a fixed angle rotor type 70ti.
Multiparametric flow cytometry analysis
The following monoclonal antibodies (mouse anti-human)
were used for flow cytometric immunophenotyping of
hMSC-EV and hMSC: CD90 FITC (Fluorescein isothio-
cyanate), CD34 FITC, CD44 PE (phycoerythrin), CD73
PE, CD14 PE, CD63 PE, CD166 PerCP-Cy 5.5 (phyco-
erythrin-cyanine 5.5), CD34 PerCP-Cy5.5, CD45 PerCP-
Cy5.5, HLA-DR PerCP-Cy5.5, CD19 PerCP-Cy5.5, CD81
APCH7 (APC-cyanine tandem dye), CD45 V500 (BD
Horizon V500), CD44 APC (Allophycocyanin) and CD105
APC. All of them were purchased from BD Biosciences
(San José, CA) except for CD44 APC, Cytognos (Sala-
manca) and CD105 (R&D Systems, Minneapolis, MN,
USA) purchased from Cytognos and R&D systems, re-
spectively. We used a FACSCalibur flow cytometer (BD
Biosciences) for hMSC sample acquisition. The FACSCali-
bur flow cytometer is a 4-color instrument with two la-
sers, blue (488-nm) and red (633 nm). Labeled cells were
acquired immediately after the staining using a FACSCali-
bur flow cytometer equipped with the CellQuestTM pro-
gram (BD Biosciences).
Human MSC were characterized using the following
conjugated monoclonal antibody combinations: CD34
FITC/CD73 PE/CD45 PerCPCy5.5/CD105, CD44 FITC/
CD14 PE/CD19 PerCPCy5.5 and CD90 FITC/CD166
PE/HLA-DR PerCPCy5.5. Human MSC (5 × 105 cells)
were suspended in PBS and incubated with combina-
tions of the monoclonal antibodies described above and
also was acquired hMSC unstained used as control.
We used a FACSCanto II flow cytometer (BD Biosci-
ences San Jose, CA) for EV acquisition using the FACS-
Diva 6.1 software (BD Biosciences). The FACSCanto II
flow cytometer is an 8-color instrument with 3 lasers,
blue (488-nm, air cooled, 20-mW solid state), red
(633 nm, 17-mW HeNe) and violet (405 nm, 30-mW solid
state).
For FACSCanto II flow cytometer calibration, we used
SPHERO™ Rainbow Calibration Particles (Rainbow Cali-
bration, eight peaks-Spherotech, Inc. Lake Forest, USA),
following the recommendation of the EuroFlow consortium
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[50], with adaptation of light scatter detectors channels to
properly identify the EV. For fluorescence compensation,
BD™ CompBeads (BD Biosciences, San José, CA, USA)
were used with generic and with the fluorochrome-label
antibodies used in our experiments. Samples were ac-
quired after daily evaluation of instrument’s performance
using the Rainbow beads particles. These particles were
also used to identify the electronic noise or background,
which comes primarily from extraneous particles reaching
the detector (light scatter) [9]. The samples were acquired
after the cytometer was calibrated and compensated.
Before EV acquisition, the instrument was washed with
rinse solution and with double filtered PBS (through
0.2 μm membrane Millipore filters) after 6 h of sedimen-
tation, to reduce the instrument background noise
(Fig. 1). The forward scatter component (FSC) param-
eter is used to determine the EV size. Double-filtered
PBS was acquired with a mix of fluorescent beads com-
posed of varied diameters (0.5, 0.9 and 3 μm) Megamix
(Biocytex, Marseille, France) and perfect-Count Microe-
spheres (Cytognos, Salamanca, Spain) of 6–6,4 μm in size.
The beads of different sizes were used in all of the experi-
ments, with this approach we validated our instrument
basis on the capacity to discriminate between 0.5 and
0.9 μm Megamix beads using the FSC parameter, as well
as their background noise. The acquisition of the samples
was only performed when the number of double-filtered
PBS events acquired per second ranged between 25 and
50 at low speed with threshold settings between 300 and
350. EV recovered from ultracentrifugation were sus-
pended in double filtered PBS and stained by direct im-
munofluorescence using monoclonal antibodies. For the
study of antigen expression, samples were incubated in
the dark with the appropriate combination of monoclonal
antibodies during 15 min. For the optimization of the
immunophenotypic characterization of EV released from
hMSC by FCM, in the immunophenotypic panel hMSC
markers (CD90, CD44 and CD73), negative markers of
hMSC (CD34 and CD45) and EV markers (CD81 and
CD63) were included. Samples were incubated for 15 min
in the dark using an 6-color combination, set up with the
following monoclonal antibody panel: 5 μl of anti-CD90-
FITC/ 10 μl of anti-CD73-PE or anti-CD63-PE/10 μl of
anti-CD34-PerCPCy5.5/5 μl of anti-CD44-APC/ 5 μl of
anti-CD81-APCH7/5 μl of anti-CD45-V500. After incuba-
tion the excess of antibodies was washed with double fil-
tered PBS at 2000 g for 10 min. The final volume
(suspended cells, MoAbs, PBS and 500 μl Megamix beads)
was 700 μl.
To analyze if the antibodies indicated above do not
form aggregates we used as negative control the double-
filtered PBS containing each single antibody as well as
the combination of all the antibodies used. The doubled
filtered PBS was stained following the same methodology
as EV (Additional file 1: Figure S2 and Additional file 2:
Figure S3). Data were acquired immediately after the
staining. In all samples, EV not labeled with the different
antibodies were used to discriminate the positive and
the negative population.
A total of 100,000 events were acquired (at low speed).
Data were analyzed using the Infinicyt program (Cytognos,
Salamanca, Spain).
Immunoblotting
Ultracentrifuged EV were re-suspended in lysis buffer
(25 mM HEPES, pH 7.5, 150 mM NaCl, 1%Igepal, 10 %
glycerol, 10 mM MgCl2, 1 mM EDTA, 25 mM NaF,
1 mM Na2VO4, plus proteinase inhibitors), and incubated
20 min on ice. Non-soluble material was eliminated by
centrifugation. Protein concentrations were determined
using the Bradford assay. Samples were then subjected to
SDS-PAGE and the proteins were transferred onto Polyvi-
nylidene fluoride (PVDF) membranes from GE Healthcare
(Barcelona, Spain), as previously described [51]. Non-
specific binding was blocked with 5 % non-fat dry milk.
Primary antibodies were rabbit α-CD63 and α-CD81 (Exo
AB Antibody Kit – System Biosciences) and rabbit α-
CD73 (ab124725, Abcam Inc.). Incubation with the
primary antibodies at the appropriate dilution was
performed overnight at 4 °C. As secondary antibody
an anti-rabbit IgG horseradish peroxidase-conjugated
from Amersham Biosciences was used. Incubation with
the secondary antibody was performed at room tempera-
ture for 1 h. Blots were visualized using chemilumines-
cence using ECL-Plus reagent (Amersham Biosciences).
Transmission electron microscopy
EV pellets were re-suspended in PBS and fixed in 2 %
paraformaldehyde (PF) and 2.5 % glutaraldehyde and
stained with uranyl-oxalate solution. The images were
captured using a transmission electron microscopy (FEI-
Tecnai G2 Spirit Biotwin) using a digital camera (Morada,
Soft Imaging System, Olympus).
Nano-particle tracking analysis
Analysis of absolute size distribution of EV was per-
formed using NanoSight NS 300 (NanoSight Ltd., UK)
equipped with a sCMOS camera. This technology is
based on the assessment of both light scattering and
Brownian motion to obtain the size distribution and
concentration measurement of particles in liquid sus-
pension. After isolation, the EV were diluted in 1 ml of
doubled filtered PBS. The NTA measurement conditions
were as follows: temperature between 21 and 23.6 °C;
viscosity between 0.9 and 0.965 cP, frames per second
25, measurement time 60s. Before acquisition the sam-
ples were diluted in water (1:1000) due to their high
concentration. The detection threshold was similar in all
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samples. The results indicate the mean sizes and stand-
ard deviations of at least three individual measurements.
Results
hMSC definition criteria
hMSC were isolated and expanded from BM samples and
further characterized according to ISCT minimal defin-
ition criteria [28]. These cells did not express hematopoie-
tic lineage markers such as CD14, CD19, CD34, CD45
and HLA-DR, and were positive for CD73, CD90, CD105,
CD166 and CD44 thereby demonstrating a characteristic
immunophenotype of hMSC In addition, their multiline-
age differentiation ability (into osteogenic, adipogenic and
chondrogenic lineages) was demonstrated (Fig. 2). HTERT
and H-S5 were also inmunophenotypically characterized
using the same panel used for hMSC from BM.
hMSC–EV flow cytometry analysis
EV were purified by ultracentrifugation collected from
the three cell lines (HTERT, HS-5 and K562) and
Fig. 1 Representative FCM dotplot showing acquired PBS 0.22 μm doubled filtered (a) and PBS doubled filtered with beads (0.5, 0.9, 3, 6–6.4 μm)
(b). All samples used in this work were acquired when positive events were not present in the different fluorescence channels in the acquired
PBS (double filtered)
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primary BM-hMSC, including hMSC-GFP+. After EV
isolation, all the samples were labeled with the same
panel of monoclonal antibodies. To identify EV obtained
from hMSC, the mesenchymal markers CD90, CD44
and CD73 were used. The tetraspanin CD81 and CD63
were used as EV markers.
We were able to characterize EV released from BM-
hMSC (Fig. 3), and in order to separate true events from
background noise, EV were defined as particles that
were less than 0.9 μm of diameter and were positive for
the specific markers used. Dot plot images showed that
EV were positive for CD90, CD44 and CD73, thus
Fig. 2 Characterization of human MSC. a Representative dot-plots of stained hMSC. b In vitro differentiation of hMSC to adipocytes (a, d),
osteoblast (b, e) and chondrocytes (c, f) with differentiation medium (d, e, f) compared to control (a, b, c)
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Fig. 3 (See legend on next page.)
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demonstrating that hMSC were the cell of origin (Fig. 3a).
Because there are no specific markers for hMSC but a
combination of positive and negative markers, we used
CD34 and CD45 (hematopoietic markers) to demonstrate
the specificity of monoclonal labeling. As shown in
the dot plots, hMSC- EV were negative for these
hematopoietic markers. Our results (Fig. 3a) showed that
besides being positive for mesenchymal markers, negative
for hematopoietic markers and with a size less than
0.9 μm, hMSC-EV were also positive for CD63 and CD81.
In our study we also used BM-hMSC transduced with
a lentiviral vector containing the GFP gene. Once trans-
duced, the cells express GFP that can be detected by
FCM. Our results (Fig. 3b) showed that EV from hMSC-
GFP+ also express GFP. Performing a live-gate on the
positive events in the fluorescence-1 channel (where
GFP is detected), we showed that this population was
also positive for CD73 and CD44 (hMSC marker), and
for CD81 and CD63 (EV marker). At the same time this
population was negative for hematopoietic markers with
sizes smaller than 0.9 μm.
To confirm that this immunophenotypic panel was
specific to characterize hMSC–EV, EV from three cell
lines were analyzed: hTERT and HS-5 that are human
mesenchymal cell lines and K562 that is a leukemia cell
line used as negative control. As shown in Fig. 4, EV iso-
lated from conditioned medium of hTERT and HS-5 cell
lines, expressed the same immunophenotypical profile
than EV from BM-hMSC. However EV obtained from
K562 cell line did not show hMSC markers.
The use of controls in flow cytometry for EV characteri-
zation is very important. In a set of experiments to ensure
that the population analyzed are EV and no other signals
we acquired only Megamix (Additional file 3: Figure S1),
doubled filtered PBS stained with each different antibody
in an individual tube (Additional file 1: Figure S2), dou-
bled filtered PBS with the combination of all the different
antibodies (Additional file 2: Figure S3), unstained EV-
hMSC and stained with each different antibodies in an in-
dividual tube (Additional file 4: Figure S4 and Additional
file 5: Figure S5).
Characterization of hMSC-EV
The morphology of EV was confirmed by phase-contrast
transmission electron microscopy [29]. We observed
typical bilayer-membrane vesicles with heterogeneous size
from isolated EV of BM-hMSC and MSC cell lines
(Fig. 5a). K562-EV also showed the characteristic rounded
morphology with a hypodense center. Western blot ana-
lysis showed that EV from all conditioned media ex-
pressed the specific markers of EV (CD63 and CD81) and
the EV from MSCs were also positive for the mesenchy-
mal marker CD73 (Fig. 5b).
Next, we characterized EV from different sources to
determine their size with an independent method, nano-
particle tracking analysis. High particle concentration
was detected in all samples (Table 1) being highest in
hTERT and hMSC-EV. Size was homogenous between
the different EV samples (Fig. 6). NTA estimated that
the size of EV-hMSC was between 35 and 695 nm.
These results are in agreement with the current rec-
ommendations of the International Society for Extracel-
lular Vesicles (MISEV) [30, 31].
Discussion
Human MSC have emerged as one of the most promising
cell type with potential clinical applications in cellular
therapy programs [32]. Besides the direct differentiation
potential into some cell types (e.g. osteoblasts for bone re-
pair) [33], they exert their therapeutic effect mostly by
paracrine secretion of cytokines and other mediators [8].
In addition, in the last few years it has been shown that
hMSC also act through the secretion of EV. The use of
MSC-derived EV has potential advantages over the
use of the cells, including the theoretical absence of
risk of malignant transformation and less regulatory
hurdles for clinical application, since it is a cell-free
therapeutic product [34].
EV can be isolated by different methods, and their
characterization in most experiments is based on their
structure/morphology by TEM, or on the tetraspanin ex-
pression by Western blot. There are other additional
methods that have been applied to the detection and quan-
tification of EV, including atomic force microscopy (AFM)
[35], dynamic light scattering (DLS) [36], nanoparticle
tracking analysis [37, 38] or resistive pulse sensing (RPS)
[29]. Nevertheless, there is a need for a fast, reproducible
and generalized method for identification of EV that takes
into account not only their size but also their cell of
origin.
(See figure on previous page.)
Fig. 3 Multiparametric analysis of EV-hMSC. a Representative FCM dotplots showing the gate protocol for hMSC-EV. The gate of EV was defined
by use of microbeads. Standard microbeads with a diameter of 0.9 μm were used to set the upper size limit for the EV and were used to gate
the hMSC-EV. hMSC-EV stained with hematopoietic markers (CD34 and CD45) were negative and were positive for hMSC markers (CD90, CD44,
CD73) and for EV markers (CD81 and CD63). In gray represents the control (unstained EV) and in black the EV stained with the different anti-
bodies. b Representative dotplot of EV from hMSC-GFP+, in these case we first gate the particles that were positive in fluorescence 2 (GFP) and
were also smaller than the upper size (0.9 μm). Then we confirmed with these gate that the EV from hMSC-GFP+ were positive for mesenchymal
markers, negative for hematopoietic markers and positive for CD63 and CD81 (EV markers)
L. Ramos et al. Cell Communication and Signaling  (2016) 14:2 Page 8 of 14
Fig. 4 EV analysis of the different mesenchymal cell lines (hTERT and HS-5) and leukemia cell line (K562) the data is represented in dotplots. EV
stained with hematopoietic markers (CD34 and CD45), positive markers for hMSC (CD90, CD44, CD73) and for EV markers (CD81 and CD63).
a EV-hTERT cells. b EV- HS-5. c EV-K562
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For EV quantification the methodologies most widely
used are NTA and FCM. The studies that compare these
two methods discuss that they cannot be interchangeable
since the size range that they can analyze is different.
NTA allows obtaining and comparing size distribution
mainly in particles less than 300 nm, what gives more ac-
curate counts compared with FCM. However, FCM is a
powerful technique for multiparametric analysis of single
biological particles allowing the differentiation of distinct
cellular origins [25, 29, 39].
In our opinion, FCM has the potential to characterize
EV, but the identification of hMSC- EV is not a currently
standardized process. We have used in the current work a
flow cytometer FACSCanto II maintaining the standard
cell based setup of the instrument unmodified as much as
possible, to assess the potential viability of this type of
measurements in a clinical routine used instrument. Thus,
we established a protocol to provide an identification
strategy that could be easily followed in most clinical insti-
tutions. The use of FCM for EV characterization has some
limitations, because the method presented herein only al-
lows analysis of EV above the threshold of detection of the
instrument, and potentially excludes smaller particles
below this threshold [40, 41]. In the last years, different
groups have generated protocols of standardization in
order to improve instrument performance and resolution.
This new high sensitive flow cytometer with high light-
scatter sensitivity, an optimized laser beam shaping and
detectors are an improvement over the standard flow cyt-
ometers, which were unable to detect small particles. Sev-
eral studies have reported other methodologies to detect
EV by FCM, fluorescence-triggered detection is one of
them. They demonstrated several advantages over light-
scatter triggering signals with highly sensitive of EV
detection.
There are a number of questions that need to be con-
sidered for an adequate identification and characteriza-
tion of MSC-EV by FCM, which will be briefly discussed
in the next paragraphs.
Fig. 5 Representative images for validation of EV using TEM (a) and Western Blot (b). a I-EV-K562 cells. II-EV- BM-hMSC. III-EV-HS-5 and IV-EV-hTERT
mesenchymal cell lines. Scale bar 500 nm. Original magnification: ×8000. b WB analysis of human mesenchymal protein CD75 (I) and human
exosomal CD63 and CD81 proteins (II and III, respectively)
Table 1 Mean size and concentration of EV from HS.5, hTERT,
K562 and hMSC culture measured by NTA
EV Concentration (particles/mL) Size (nm)
HS.5 3,29 × 1011 ± 2,4 × 1010 Mean – 125.6
SD – 49.8
hTERT 7,64 × 1011 ± 4,62 × 1010 Mean – 159,7
SD – 130,4
K562 3,36 × 1011 ± 5,05 × 1010 Mean – 122
SD – 65,9
hMSC 6,40 × 1011 ± 1 × 1010 Mean – 136,6
SD – 86,8
SD standard deviation calculated by NTA software. Numbers represent average
values ± standard deviation (n = 3 measurement)
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The first one is related to the selection of the mono-
clonal antibodies to be included in the identification
panel. In this regard, we have selected antibodies that
identify tetraspanins that are typically expressed by exo-
somes (CD81, CD63) [42], together with antibodies that
recognized markers expressed by MSC in their membrane
(CD90, CD44 and CD73) [43] and those that are consist-
ently negative in MSC and positive in hematopoietic stem
cells or endothelial cells (CD34) or in leukocytes (CD45).
With this strategy we can differentiate by FCM those EV
derived from MSC from those derived from HSC or from
any leukocyte [44].
The second important factor for the identification of
EV by FCM is the inclusion of two sets of microbeads of
different sizes (a Megamix Kit of 0.5, 0.9 and 3 μm and a
perfect-Count Microespheres of 6–6,4 μm in size). The
inclusion of microbeads helps not only to define the
upper forward scatter EV size gate limit, but this strategy
also allows to correctly define the threshold level
necessary to strictly acquire EV avoiding the instrument
background noise [26, 45].
The third important issue is to adequately confirm the
calibration and the right compensation of the flow cyt-
ometer before initiating the acquisition of EV. The signal
acquired by FCM of small particles is not only influ-
enced by particle size but also by their refractive index,
surface roughness, shape and possible light observation.
Many efforts are aimed to EV standardization measure-
ments by FCM for their correctly identification that in-
clude sample preparation, immunostaining and particle
size-calibration protocols [41].
To minimize the background noise it is critical to ac-
quire the data at low flow speed to increase the reso-
lution as well as for the accurate discrimination between
non-fluorescence noise and fluorescence signals. High
flow speed increases the diameter of the sample stream
that lets the particles move outside the center of the laser
spot decreasing the resolution. Another critical issue to
Fig. 6 EV quantification using Nanosight nanoparticle tracking analysis. hMSC cells produced EV in cell culture with a mean size of 136 ± 86,8
nm, with a homogenous EV population. Cell lines hTERT and HS.5 (mesenchymal lines) and K562 cells (Leukemia cell line) also produce EV with
size similar to EV–hMSC a - EV-K562; b - EV-BM-hMSC; c - EV-HS-5; d - EV-hTERT
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reduce the background noise is the use of 0.22 μm fil-
trated PBS, which reduces the number of small events re-
corded by FCM [29].
Controls are the most important and relevant informa-
tion required to ensure that we detected EV and no un-
specific signals. We performed a set of control assays to
ensure the correct EV detection. Because we used FCM
for EV detection with a closer methodology used in the
mainly clinical research facilities some limitations were
detected. One of them is that not all the EV population
was detected and characterized because we only de-
tected EV with size between 0.3 and 0.9 μm. NTA assays
reveal the presence of a EV population with sizes inferior
to 0.3 μm, which reveals that not all the EV population by
our FCM are detected. Other limitation identified during
control assays is the fact that EV are very small, we cannot
be sure that the signal of one particle in one laser really
corresponds at the same particle under the second laser
that can be wrongly computed. One way of overcoming
this problem is the use the fluorescence triggering
approach.
To further confirm that our FCM identification strat-
egy we have isolated EV from BM-hMSC transduced
with a lentiviral vector containing the GFP gene, to
unequivocally demonstrate that our protocol identifies
these EV by the GFP expression. Although some authors
use a cell tracker (e.g. Vibrant Cell, DiD or similar) for
identification of EV and also for EV tracking in cellular
incorporation studies, their use for FCM characteriza-
tion may generate positive events due to the fluores-
cence overlap in other channels. Once transduced, the
cells express GFP that can be detected by FCM avoiding
the false positive events.
In addition to these confirmatory experiments, we
have tested our strategy not only in primary hMSC-
derived EV but also on EV secreted by two profusely
employed mesenchymal stromal cell lines, hTERT and
HS-5. EV derived from both cell lines can be easily iden-
tified by FCM following the protocol described in our
study. By contrast, EV from one leukemia cell line
showed a different expression profile.
Conclusions
We have described a methodology to identify and char-
acterize by flow cytometry hMSC-derived EV. The
method is reproducible and reliable, and may be easily
applied for EV characterization in most institutions and
experimental settings.
Additional files
Additional file 1: Figure S2. Representative FCM PBS dotplots.
Doubled filtered PBS mixed with one antibody per tube. (TIF 528 kb)
Additional file 2: Figure S3. Multiparametric FCM PBS dotplots.
Doubled filtered PBS mixed with a combination of all different
antibodies. (TIF 315 kb)
Additional file 3: Figure S1. Detection by FCM of different size beads.
Dotplot of Megamix (0.5, 0.9 and 3 μm) and 6–6.5 μm beads dotplot (A)
and density histogram (B). (TIF 120 kb)
Additional file 4: Figure S4. Unstained hMSC-EV dotplots. (TIF 494 kb)
Additional file 5: Figure S5. Representative individual dotplots of
hMSC-EV. (A) Dotplots of hMSC-EV stained with each different antibody
per tube. (B) Mean fluorescence intensity (MIF) values of the different
channels. (TIF 633 kb)
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